Literature DB >> 23686498

Programmed death-1 shapes memory phenotype CD8 T cell subsets in a cell-intrinsic manner.

Joanna J Charlton1, Ioannis Chatzidakis, Debbie Tsoukatou, Dimitrios T Boumpas, George A Garinis, Clio Mamalaki.   

Abstract

Memory phenotype T cells, found in unimmunized mice, display phenotypic and functional traits of memory cells and provide essential protection against infections, playing a role in both innate and adaptive immune responses. Mechanisms governing homeostasis of these memory phenotype T cells remain ill-defined. In this study, we reveal a crucial role of the negative costimulator programmed death-1 (PD-1) in regulating developmental fates of memory phenotype cells. Thus, in lymphoid organs and tissues of PD-1 knockout (KO) mice a marked accumulation of functional effector memory (T(EM)) phenotype CD8 T cells was observed. T(EM) phenotype cells from PD-1 KO mice exhibit decreased proliferation but increased survival potential. These cells could produce effector molecules constitutively, in response to phorbol esters or through bystander activation by innate stimuli. Similarly, in lymphopenia-induced proliferating CD8 T cells, whereby normally naive T cells acquire a memory phenotype, skewing toward a T(EM) phenotype was prominent in the absence of PD-1. Acquisition of the T(EM) phenotype was a CD8 T cell-intrinsic phenomenon as demonstrated by mixed bone marrow transfer experiments. Importantly, adoptively transferred PD-1 KO CD8 central memory T (T(CM)) cells converted into the T(EM) phenotype, indicating that PD-1 sets a major checkpoint in the T(CM) to T(EM) phenotype differentiation process. This was reflected by distinct patterns of gene expression of PD-1 KO T(CM) phenotype cells revealed by global transcriptional analysis. Additionally, adoptively transferred PD-1 KO T(EM) phenotype cells converted to a lesser degree to a T(CM) phenotype. Collectively, these data suggest that PD-1 shapes memory phenotype CD8 T cell subsets.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23686498     DOI: 10.4049/jimmunol.1201617

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  27 in total

Review 1.  Metabolic Barriers to T Cell Function in Tumors.

Authors:  Ayaka Sugiura; Jeffrey C Rathmell
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

Review 2.  Autoimmune effector memory T cells: the bad and the good.

Authors:  Priyadharshini Devarajan; Zhibin Chen
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

3.  PD-1 expression on CD8+ T cells regulates their differentiation within lung allografts and is critical for tolerance induction.

Authors:  T Takahashi; H M Hsiao; S Tanaka; W Li; R Higashikubo; D Scozzi; A Bharat; J H Ritter; A S Krupnick; A E Gelman; D Kreisel
Journal:  Am J Transplant       Date:  2017-08-23       Impact factor: 8.086

Review 4.  Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer.

Authors:  D E Meyers; P M Bryan; S Banerji; D G Morris
Journal:  Curr Oncol       Date:  2018-08-14       Impact factor: 3.677

5.  Conserved Region C Functions To Regulate PD-1 Expression and Subsequent CD8 T Cell Memory.

Authors:  Alexander P R Bally; Yan Tang; Joshua T Lee; Benjamin G Barwick; Ryan Martinez; Brian D Evavold; Jeremy M Boss
Journal:  J Immunol       Date:  2016-11-28       Impact factor: 5.422

6.  p53 Hinders CRISPR/Cas9-Mediated Targeted Gene Disruption in Memory CD8 T Cells In Vivo.

Authors:  Samarchith P Kurup; Steven J Moioffer; Lecia L Pewe; John T Harty
Journal:  J Immunol       Date:  2020-09-04       Impact factor: 5.422

7.  Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation.

Authors:  Tom B Davidson; Alexander Lee; Melody Hsu; Shaina Sedighim; Joey Orpilla; Janet Treger; Max Mastall; Saskia Roesch; Carmen Rapp; Mildred Galvez; Aaron Mochizuki; Joseph Antonios; Alejandro Garcia; Nikesh Kotecha; Nicholas Bayless; David Nathanson; Anthony Wang; Richard Everson; William H Yong; Timothy F Cloughesy; Linda M Liau; Christel Herold-Mende; Robert M Prins
Journal:  Clin Cancer Res       Date:  2018-11-29       Impact factor: 12.531

8.  PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.

Authors:  Dmitriy Zamarin; Jacob M Ricca; Svetlana Sadekova; Anton Oseledchyk; Ying Yu; Wendy M Blumenschein; Jerelyn Wong; Mathieu Gigoux; Taha Merghoub; Jedd D Wolchok
Journal:  J Clin Invest       Date:  2018-03-05       Impact factor: 14.808

9.  Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody.

Authors:  Lavakumar Karyampudi; Purushottam Lamichhane; Adam D Scheid; Kimberly R Kalli; Barath Shreeder; James W Krempski; Marshall D Behrens; Keith L Knutson
Journal:  Cancer Res       Date:  2014-04-11       Impact factor: 12.701

Review 10.  The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity.

Authors:  Suzanne Ostrand-Rosenberg; Lucas A Horn; Samuel T Haile
Journal:  J Immunol       Date:  2014-10-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.